Brown's Larkspur (Delphinium brunonianum Royle): A Comprehensive Reference
Identity
Botanical and Taxonomic Classification
Brown's larkspur is the common English name for Delphinium brunonianum Royle, a perennial herbaceous flowering plant. Delphinium brunonianum Royle belongs to the genus Delphinium within the family Ranunculaceae, and is a perennial herbaceous plant. This species is native to Central Asia, Afghanistan, Pakistan, Tibet, and the Himalaya, and can be found on stony mountain slopes and screes at elevations of 4,300–5,500 metres (14,100–18,000 ft) above sea level. Other documented sources place its altitudinal distribution somewhat more broadly: it is mainly distributed at an altitude of 4,000–6,000 m from the Tibet Autonomous Region of China to Nepal and Afghanistan.
The genus name Delphinium is of Greek origin. The genus name Delphinium derives from the Ancient Greek word δελφίνιον (delphínion), meaning "dolphin" — a name used in De Materia Medica for some kind of larkspur; Pedanius Dioscorides said the plant got its name because of its dolphin-shaped flowers. The species epithet brunonianum commemorates early botanical collectors associated with the plant's discovery in the Himalayas.
Within the broader genus, delphiniums belong to the Delphinium genus, while larkspurs in the narrower modern sense are part of the Consolida genus. The common name "larkspur" is shared between perennial Delphinium species and annual species of the genus Consolida. Delphinium brunonianum, as a perennial species, is firmly placed in the genus Delphinium rather than Consolida.
The plant is also referred to in sources as the Himalayan larkspur, reflecting its geographic concentration in the high Himalayas. It is also sometimes called musky larkspur, in reference to a distinctive musky scent from glandular hairs on the plant. Its documented geographic range spans southern Tibet, Iraq (NE Iraq), Tajikistan, Jammu and Kashmir, Himachal Pradesh, Uttar Pradesh (India), Nepal, Pakistan (including the Pamirs, Kurram, Chitral, Hazara, Gilgit, Baltistan, and Ladakh), and Afghanistan.
Morphological Description
Delphinium brunonianum Royle is a perennial herb with dark blue to purple flowers, wildly growing in Shilla Valley at 4,425 m elevation in Skardu Baltistan, Pakistan. The herb grows in clumps, typically 20–40 cm tall, with palmate leaves and slender stems; its signature sky-blue to violet flowers appear in loose racemes. The leaves are deeply lobed with three to seven toothed, pointed lobes in a palmate shape.
Common Forms and Preparations Used
The dried aerial parts of D. brunonianum are used medicinally. In research contexts, preparations have included crude hydroalcoholic (methanol or ethanol) extracts of the aerial parts, butanolic fractions derived from those crude extracts, and isolated purified alkaloid fractions. In laboratory investigations, dried and powdered aerial parts have been repeatedly extracted with methanol at room temperature, with each extraction lasting 24 hours, and the extracted solution evaporated under vacuum to yield a crude methanol extract. Topical preparations (tinctures and lotions) have historically been made from seeds or flowering plant material of related larkspur species for ectoparasitic use.
Traditional and Historical Use
Tibetan Medicine
The dried aerial parts of D. brunonianum, known as a traditional Chinese aboriginal medicine named "Qiagaobei" in Tibetan, have been widely used for a long time in the treatment of jaundice, influenza, skin itching, and snake bites, due to its properties of cooling blood, clearing heat, and detoxification. According to the Tibetan Medical Theory in Shel Gong Shel Phreng, it is commonly used in the treatment of liver disease.
D. brunonianum, belonging to the Delphinium genus (Ranunculaceae family), usually has the effects of clearing heat, detoxifying, anti-inflammatory, and analgesic as a folk medicine. This corresponds to a classical Tibetan medical framework in which "heat-clearing" herbs are employed for inflammatory, infectious, and febrile conditions.
Use in Gilgit-Baltistan and Northern Pakistan
The plant grows wildly in Skardu Baltistan, Pakistan, and from ancient times has been used by the local people of Gilgit Baltistan for curing various illnesses, including asthma, pneumonia, cough, stomachache, and controlling blood pressure and jaundice. The literature also indicates that it has been used as a natural pesticide against lice and scorpions.
Broader Larkspur Traditions
Within related Delphinium and larkspur species, the antiparasitic use is well attested across many cultures and periods. As in Stavesacre, the part used medicinally is the seed; a tincture acts as a parasiticide and insecticide, being used to destroy lice and nits in the hair. The flowers and leaves were extensively used in the United States Army during the Civil War rebellion to kill lice. Larkspur was made into a lotion or tincture for topical application to kill lice, crabs, and other parasites.
Indigenous communities in North America also documented medicinal uses of various larkspur species. Larkspur flowers were used to make a weak tea to help children who had bad diarrhea, and a weak tea would be given to children who had fainting spells or were foaming at the mouth. A tea was also used to help make a woman's hair shiny and straight, while a strong tea was used to dye the quills of arrows to make them blue in color.
The historical use of larkspur dates back centuries, particularly in Central and South Asia, where it was revered for its multifaceted therapeutic properties; healers and herbalists commonly employed Brown's Larkspur as a remedy for parasitic infestations, most notably lice and scabies. Historically, extracts from Brown's Larkspur have been used in various cultures to address ailments such as digestive issues, inflammation, and as a general tonic.
Key Constituents and Active Compounds
Primary Phytochemical Classes
Phytochemical research has established that alkaloids, flavonoids, and sterols are the predominant composition of D. brunonianum. Among them, diterpenoid alkaloids are the characteristic constituents with complex structural features, which mainly include lycoctonine-type C19 and atisine-type C20 diterpenoid alkaloids.
Past research has shown that the alkaloids are the main constituents, and flavonoids and sterols were also found, with reported effects including antibacterial, antiepileptic, detoxification, and Alzheimer's disease treatment.
Diterpenoid Alkaloids
The most extensively studied chemical class in D. brunonianum is the diterpenoid alkaloids. Four novel diterpenoid alkaloids — brunodelphinine B, C, D, and E — have been isolated from D. brunonianum together with eleven known diterpenoid alkaloids through phytochemical investigation. Earlier work had yielded three further named alkaloids: three new C19-diterpenoid alkaloids — delbrunine, delbruline, and delbrusine — were isolated from D. brunonianum Royle and their structures elucidated.
Additional work isolated three novel C19-type diterpenoid alkaloids (Brunonianines D, E, and F) from D. brunonianum; their structures were elucidated by 1D/2D NMR, HR-ESI-MS, and single-crystal X-ray diffraction analyses. Prior work had also described Brunonianines A–C as C20-diterpenoid alkaloids bearing a cyano group.
Other identified compounds include Delbrunine, 4-O-α-D-Glucosyl benzoic acid, Kaempferol 3-O-β-D-glucopyranoside 7-O-α-L-rhamnopyranoside, and Eldeline. In insecticidal research, delpheline, delbrunine, eldeline, and delsoline were isolated and identified, with eldeline, delsoline, and delbrunine showing toxicity against Diaphorina citri.
Non-Diterpenoid Alkaloids
Five new acyl anilines — delamides A–E — which possess an O-ester aniline bearing an amide side chain, were isolated from D. brunonianum. These belong to the class of amide alkaloids distinct from the diterpenoid backbone.
Broader Delphinium Alkaloid Context and Mechanisms
Phytochemical investigations on Delphinium plants over the last four decades (1980–2019) afforded a total of 453 new compounds, most of which are diterpenoid alkaloids; these constituents are of great research significance due to their novel structures and broad bioactivities.
The toxic mechanism of norditerpenoid alkaloids in the Delphinium genus is well characterized from veterinary toxicology: intoxication results from neuromuscular paralysis, as nicotinic acetylcholine receptors in the muscle and brain are blocked by toxic alkaloids; clinical signs include labored breathing, rapid and irregular heartbeat, muscular weakness, and collapse. These alkaloids block nicotinic acetylcholine receptors in the brain and periphery of the body. The most toxic subclass, the MSAL-type alkaloids (principally methyllycaconitine, MLA), are 20–30 times more toxic than non-MSAL-type alkaloids in the mouse model.
Scientific Evidence by Area of Use
1. Anti-inflammatory Activity
Evidence type: In vitro (cell-based), preclinical only. No human clinical trials identified.
A peer-reviewed study published in Frontiers in Nutrition (2021) investigated the anti-inflammatory properties of isolated compounds from D. brunonianum. Four compounds were isolated and identified: Delbrunine (1), 4-O-α-D-Glucosyl benzoic acid (2), Kaempferol 3-O-β-D-glucopyranoside 7-O-α-L-rhamnopyranoside (3), and Eldeline (4); their anti-inflammatory activity was screened in RAW264.7 cells; the results showed that compounds 2 and 3 had weak anti-inflammatory activities, while compounds 1 and 4 had good anti-inflammatory activity.
The macrophage inflammation model was established by lipopolysaccharide (LPS); anti-inflammatory activity was evaluated by ELISA kits, qRT-PCR, and western blot, while anti-oxidative stress activity was assessed by flow cytometry; the results showed that compounds 1 and 4 could significantly inhibit the elevation of inflammatory factors nitric oxide (NO), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and also had obvious inhibitory effects on the production of inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2).
In addition, compounds 1 and 4 could effectively inhibit the overexpression of reactive oxygen species (ROS) in RAW264.7 cells activated by LPS; these results indicated that compounds 1 and 4 may exert anti-inflammatory and anti-oxidative stress effects through the NF-κB signaling pathway.
Strength of evidence: Preliminary. All findings are from in vitro cell culture models. No animal studies or human trials have been conducted on this specific activity.
2. Hepatoprotective / Lipid-Lowering Activity (NAFLD and Hyperlipidemia)
Evidence type: In vitro and in vivo animal studies. No human clinical trials identified.
A 2022 study published in Molecules (PMC-indexed) investigated the effects of diterpenoid alkaloids from D. brunonianum on hepatocyte lipid accumulation. The inhibitory effects of 15 diterpenoid alkaloids on hepatocyte lipid accumulation were evaluated using a fatty acid mixture to induce buffalo rat liver (BRL) cells; five diterpenoid alkaloids — brunodelphinine E, delbruline, lycoctonine, delbrunine, and sharwuphinine A — exhibited significant inhibitory effects on lipid accumulation in a dose-dependent manner and without cytotoxicity, with sharwuphinine A displaying the strongest inhibition.
The research provided experimental and theoretical evidence for active ingredients from this herbal medicine in the treatment of diseases related to lipid accumulation, such as non-alcoholic fatty liver disease (NAFLD) and hyperlipidemia.
More recent work has focused on a specific alkaloid: Brunodelphinine A (BruA) is a novel diterpenoid alkaloid isolated from D. brunonianum Royle. According to Tibetan Medical Theory in Shel Gong Shel Phreng, the plant is commonly used in the treatment of liver disease; in vitro research showed that D. brunonianum extract enriched with diterpenoid alkaloids could alleviate NAFLD by reducing lipid accumulation and inflammation in the liver.
Strength of evidence: Preliminary. Results are from in vitro cell culture and experimental rodent models. No randomized controlled trials or human studies have been reported.
3. Antihypertensive and Metabolic Effects
Evidence type: Rodent studies only. No human clinical trials identified.
A study aimed at phytochemical profiling and evaluating the effect of crude extract of Delphinium brunonianum on fructose-mediated rise in blood pressure and metabolic abnormalities in rats fed on fructose (10% w/v) for 6 weeks, with treatment groups receiving doses of 250, 500, and 1,000 mg/kg of D. brunonianum crude extract concurrently with fructose. The crude extract exerted a remarkable antihypertensive effect, while sympathetic hyperactivity and hyperinsulinemia in these rats was significantly blunted, and endothelium functionality was successfully restored.
Strength of evidence: Preclinical only. Findings are restricted to a rat model of fructose-induced metabolic syndrome. Dosages used (up to 1,000 mg/kg in rodents) are not directly translatable to human dosing. No clinical evidence exists.
4. Diuretic Activity
Evidence type: Rodent studies only. No human clinical trials identified.
The aim of one study was the evaluation of the diuretic potential of Delphinium brunonianum; acute diuretic effect in rats was evaluated 8 hours after administration of various doses of crude extract, fractions, and hydrochlorothiazide, while the prolonged effect of the butanolic fraction was assessed after 7 days of oral administration in rats.
All doses of extract and fractions induced a prominent increase in urine and Na⁺ excretion with no effect on excretion of K⁺; prior administration of indomethacin and atropine considerably attenuated the diuretic effect of the butanolic fraction. Polyphenolic contents of the butanolic fraction were recorded as 28.78 µg/mg; these results suggested that Delphinium brunonianum possesses remarkable diuretic potential.
Hydroalcoholic extract and fractions obtained from D. brunonianum presented significant diuretic and natriuretic effects when given to rats through the oral route.
Strength of evidence: Preclinical only. All evidence is from rat pharmacology experiments. The mechanistic implication of the atropine-blockade result suggests involvement of muscarinic/cholinergic pathways, but this has not been validated in humans.
5. Anticancer Activity
Evidence type: In vitro and in vivo murine models. No human clinical trials identified.
A 2024 study published in Bioorganic Chemistry investigated the anticancer potential of alkaloids isolated from D. brunonianum against ovarian cancer. The toxicity of isolated compounds against Skov-3 tumor cells was assessed using the MTT assay, and in-depth in vivo and in vitro experiments were conducted specifically on compound 1 (Brunonianine D) to elucidate its mechanisms of action in terms of inducing apoptosis and inhibiting proliferation.
Brunonianine D was found to treat ovarian cancer through the Bax/Bcl-2/Caspase-3 pathway, and also inhibited the growth of tumor in mice.
Diterpenoid alkaloids and flavonols, which constitute most of the compounds isolated from Delphinium plants, have been tested for various biological activities, including cholinesterase inhibition, antimicrobial, antineoplastic, insecticidal, anti-inflammatory, and anticancer activities.
Strength of evidence: Preliminary. Data are from cell lines and mouse tumor models. These findings represent early-stage drug discovery research with a significant translational gap before any clinical application could be considered.
6. Antiparasitic and Insecticidal Activity
Evidence type: Historical documentation and in vitro/insect bioassays. No controlled human trials identified.
Insecticidal activity of Delphinium brunonianum against Diaphorina citri was studied; delpheline, delbrunine, eldeline, and delsoline were isolated and identified; eldeline, delsoline, and delbrunine showed toxicity against Diaphorina citri. The isolated alkaloids were found to inhibit the cell proliferation of SF9 cells and induce apoptosis.
Historically, seed tincture was used as a parasiticide and insecticide for destroying lice and nits in the hair, and during the Great War, when the men in the trenches used it, the results were said to be quite successful.
Strength of evidence: Traditional use is well attested across multiple cultures and historical periods. Modern laboratory work confirms insecticidal alkaloids are present. No controlled clinical trials for ectoparasitic treatment using D. brunonianum specifically have been reported.
Body Systems and Health Areas Associated with Brown's Larkspur
- Hepatic / Metabolic system: Traditionally used for jaundice; modern research has examined effects on hepatocyte lipid accumulation and NAFLD in preclinical models.
- Cardiovascular / Renal system: Rodent studies have shown antihypertensive effects and restoration of endothelium functionality in fructose-fed rats. Diuretic research has demonstrated increased urine and Na⁺ excretion in animal models.
- Immune / Inflammatory system: Isolated compounds significantly inhibited inflammatory cytokines (NO, TNF-α, IL-6) and enzymes (iNOS, COX-2) in cell culture models.
- Oncology (preclinical): Brunonianine D showed activity against ovarian cancer cells through the Bax/Bcl-2/Caspase-3 pathway and inhibited tumor growth in mice.
- Dermatological / Antiparasitic: Traditional and historical use for skin itching, scabies, and ectoparasitic infestation (lice) across multiple cultures.
- Infectious / Febrile conditions: Traditional Tibetan use for influenza and snake bite, attributed to properties of cooling blood, clearing heat, and detoxification.
Dosage Forms and Doses Reported in Studies
No standardized clinical dosage exists for Brown's larkspur, as no human clinical trials have been completed. The following dosages are reported from preclinical (animal) studies only and are presented strictly as documented in the literature:
- In the diuretic study, acute diuretic effects in rats were evaluated 8 hours after administration of various doses of crude extract, fractions, and hydrochlorothiazide (as a comparator).
- Prolonged diuretic effect of the butanolic fraction was assessed after 7 days of oral administration in rats.
- In the antihypertensive/metabolic study, treatment groups of rats received 250, 500, and 1,000 mg/kg of D. brunonianum crude extract concurrently with fructose.
- For hepatocyte lipid accumulation assays, diterpenoid alkaloids were evaluated using 0.5 mM FFA (oleate/palmitate 2:1 ratio) to induce buffalo rat liver (BRL) cells, measuring triglyceride, total cholesterol, ALT, AST, and oil red O staining.
- In traditional Tibetan practice, the dried aerial parts are used medicinally, but no standardized dose or preparation protocol has been published in accessible peer-reviewed literature.
Safety Considerations and Interactions
General Toxicity of Delphinium Alkaloids
All members of the genus Delphinium are toxic to humans and livestock. Larkspurs contain numerous diterpenoid alkaloids occurring as lycoctonine-type and 7,8-methylenedioxylycoctonine (MDL)-type; among the lycoctonine-type are three MSAL-type alkaloids — methyllycaconitine (MLA), 14-deacetylnudicauline (DAN), and nudicauline — which appear to be most toxic, with an ester function at C-18 being an important structural requirement for toxicity.
Intoxication results from neuromuscular paralysis, as nicotinic acetylcholine receptors in the muscle and brain are blocked by toxic alkaloids; clinical signs include labored breathing, rapid and irregular heartbeat, muscular weakness, and collapse.
Larkspur has a relatively weak action and is not much used medicinally today; poisoning is possible if large quantities are consumed, and seeds and young plants are particularly dangerous.
Specific Alkaloid Toxicity Profiles
The toxicity of larkspur is attributed to two types of norditerpenoid alkaloids: the 7,8-methylenedioxylycoctonine (MDL) type such as deltaline, and the N-(methylsuccinimido) anthranoyllycoctonine (MSAL) type such as the highly toxic methyllycaconitine (MLA).
The neurotoxic norditerpenoid alkaloid methyllycaconitine (MLA) was first detected in D. brownii (now reclassified as a form of D. glaucum) over 50 years ago. While MLA has been well characterized in the North American D. glaucum/brownii, the alkaloid profile of the Himalayan D. brunonianum is structurally distinct (dominated by lycoctonine-type C19 and atisine-type C20 alkaloids rather than MSAL-type compounds); nonetheless, general caution regarding Delphinium alkaloid toxicity applies.
In general, non-MSAL-type alkaloids are 20–30 times less toxic than MSAL-type alkaloids in mouse models — a distinction relevant to assessing the relative risk of D. brunonianum's principal alkaloid classes.
Pharmacological Interactions Indicated by Mechanistic Data
Prior administration of indomethacin (a cyclooxygenase inhibitor / NSAID) and atropine (a muscarinic antagonist) considerably attenuated the diuretic effect of the butanolic fraction of D. brunonianum in rats. This mechanistic finding implies potential interactions with prostaglandin-modulating drugs (NSAIDs) and muscarinic receptor-targeting medications (anticholinergics, cholinesterase inhibitors).
Delphinium alkaloids block nicotinic acetylcholine receptors in the brain and periphery of the body, suggesting the potential for pharmacodynamic interactions with neuromuscular blocking agents, nicotinic receptor agonists/antagonists, and cholinergic medications.
Conservation and Supply Concerns
Over the duration of ethnobotanical research in Nepal, prices of several rare medicinal plants of Manang increased dramatically, highlighting both the scarcity and quick disappearance of species; this example underscores the worrying trend of over-harvesting of medicinal plants and highlights the need for conservation and management. In Skardu Baltistan, Pakistan, annually, tons of Delphinium brunonianum are reported to be wasted due to not being used economically.
State of Evidence and Research Gaps
Scientific exploration into Brown's Larkspur is still in its early stages. Preliminary phytochemical analyses have revealed the presence of alkaloids, flavonoids, and other bioactive compounds, which are thought to contribute to antioxidant and anti-inflammatory effects; some laboratory studies on related Delphinium species have shown potential antimicrobial and analgesic properties, suggesting a possible rationale for traditional uses. All published pharmacological studies as of this writing are preclinical (in vitro cell culture or rodent models). No Phase I, II, or III human clinical trials for any indication have been identified in the peer-reviewed literature. The absence of human safety and efficacy data represents the single most significant gap in the evidence base.
References
Go back